Trial
NCT01342172
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Celgene
Condition
Urinary Bladder Neoplasms
Intervention
Lenalidomide
Why stopped
low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-23